Skip to main content

Table 2 Laboratory examination indexes of 3 groups of children with RMPP

From: Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in children: a clinical observation

Laboratory indexes

Group

Cases

Before treatment

After treatment

t

P

CRP (mg/dl)

Budesonide

24

56.73 ± 43.98

13.98 ± 9.06

5.49

< 0.001

Ambroxol + budesonide

28

49.99 ± 41.50

7.92 ± 4.69

5.85

< 0.001

Acetylcysteine + budesonide

30

47.09 ± 41.71

6.38 ± 1.40

5.31

< 0.001

ESR (mm/h)

Budesonide

24

58.46 ± 22.78

28.63 ± 7.68

8.42

< 0.001

Ambroxol + budesonide

28

54.32 ± 23.78

22.86 ± 5.09

8.15

< 0.001

Acetylcysteine + budesonide

30

52.30 ± 23.30

16.77 ± 2.66

8.72

< 0.001

LDH (IU/L)

Budesonide

24

587.58 ± 163.17

442.96 ± 138.87

7.96

< 0.001

Ambroxol + budesonide

28

579.14 ± 153.18

354.36 ± 129.67*

13.16

< 0.001

Acetylcysteine + budesonide

30

574.67 ± 136.54

211.57 ± 81.34*

19.95

< 0.001

WBC (109/L)

Budesonide

24

9.95 ± 3.38

7.73 ± 2.01

3.48

< 0.002

Ambroxol + budesonide

28

9.66 ± 3.24

7.82 ± 1.87

4.90

< 0.001

Acetylcysteine + budesonide

30

9.38 ± 2.88

6.61 ± 1.22

7.14

< 0.001

SF (ug/L)

Budesonide

24

398.03 ± 60.80

202.75 ± 56.59

10.31

< 0.001

Ambroxol + budesonide

28

394.43 ± 58.57

140.64 ± 21.04*

20.37

< 0.001

Acetylcysteine + budesonide

30

399.33 ± 70.02

103.80 ± 20.24*

25.60

< 0.001

  1. Annotate: * The changes in laboratory indices following therapy were compared across groups, and the difference in LDH and SF was statistically significant (X2 = 11.75, P < 0.05). Group Acetylcysteine + budesonide was superior to group ambroxol + budesonide (P0.05), whereas group budesonide was superior to group ambroxol + budesonide (P < 0.05)